Huge revenue backlog. I think we'll trade in the current range until we get a next big news. Last quarter Biogen announced they only made $300k from Aduhelm. Does it mean prescribing doctors are hesitant about giving $50k drug to their patients because they are sceptical about the clinical trial result?? Or is it because of "bottleneck" issue like biogen's ceo described...? If Aduhelm sales continues to be underwhelming, I can see less money flowing into this field. We'll see
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.81 |
Change
-0.030(1.63%) |
Mkt cap ! $307.2M | |||
| Open | High | Low | Value | Volume |
| $1.85 | $1.86 | $1.81 | $297.4K | 161.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 349 | $1.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.87 | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 28/07/2025 (20 minute delay) ? |
| CGS (ASX) Chart |